| Q27641086 | A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR |
| Q43984367 | A locust DNA-binding protein involved in gene regulation by juvenile hormone |
| Q35942523 | A pleiotropic role for the orphan nuclear receptor small heterodimer partner in lipid homeostasis and metabolic pathways |
| Q36228100 | A role for IRF3-dependent RXRalpha repression in hepatotoxicity associated with viral infections |
| Q64080174 | Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR |
| Q24677042 | Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue |
| Q34304725 | Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice |
| Q40479766 | Activation of the nuclear receptor FXR induces fibrinogen expression: a new role for bile acid signaling. |
| Q40398568 | Alpha-crystallin is a target gene of the farnesoid X-activated receptor in human livers |
| Q40528640 | Amplification and overexpression of oncogene Mdm2 and orphan receptor gene Nr1h4 in immortal PRKDC knockout cells |
| Q46231561 | Antiatherosclerotic effect of farnesoid X receptor |
| Q38760586 | Antiproliferative effect of a synthetic aptamer mimicking androgen response elements in the LNCaP cell line |
| Q34396606 | Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease |
| Q34012691 | Autoregulation of the human liver X receptor alpha promoter |
| Q38816859 | Bacterial metabolites directly modulate farnesoid X receptor activity |
| Q35737058 | Bile Acids as Hormones: The FXR-FGF15/19 Pathway |
| Q34790389 | Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element |
| Q36995617 | Bile acids regulate cardiovascular function |
| Q24291555 | Characterization of the human ABCG1 gene: liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein |
| Q43064767 | Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells |
| Q52671633 | Conservation of DNA and ligand binding properties of retinoid X receptor from the placozoan Trichoplax adhaerens to human. |
| Q43002627 | Control of human carnitine palmitoyltransferase II gene transcription by peroxisome proliferator-activated receptor through a partially conserved peroxisome proliferator-responsive element |
| Q36363120 | Coordinate transcriptional regulation of transport and metabolism |
| Q40234761 | Coordinated control of bile acids and lipogenesis through FXR-dependent regulation of fatty acid synthase |
| Q28570159 | Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor |
| Q37096585 | Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output |
| Q28585274 | Expression and regulation of multiple murine ATP-binding cassette transporter G1 mRNAs/isoforms that stimulate cellular cholesterol efflux to high density lipoprotein |
| Q43898215 | FOR, a novel orphan nuclear receptor related to farnesoid X receptor |
| Q36572561 | FXR and PXR: potential therapeutic targets in cholestasis. |
| Q34440796 | FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model |
| Q36544161 | FXR induces SOCS3 and suppresses hepatocellular carcinoma |
| Q28179104 | FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity |
| Q46897927 | FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells |
| Q28572543 | FXR-mediated regulation of eNOS expression in vascular endothelial cells |
| Q37282312 | FXR: a metabolic regulator and cell protector |
| Q37587745 | Farnesoid X receptor (FXR) gene deficiency impairs urine concentration in mice |
| Q28191058 | Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression |
| Q34551962 | Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription |
| Q38115716 | Farnesoid X receptor alpha: a molecular link between bile acids and steroid signaling? |
| Q43899918 | Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump |
| Q35786712 | Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression |
| Q35187047 | Farnesoid X receptor represses hepatic human APOA gene expression |
| Q33674312 | Farnesoid X receptor, a novel proto-oncogene in non-small cell lung cancer, promotes tumor growth via directly transactivating CCND1. |
| Q34727267 | Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion |
| Q28571177 | Farnesoid X receptor, through the binding with steroidogenic factor 1-responsive element, inhibits aromatase expression in tumor Leydig cells |
| Q28253815 | Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis |
| Q38305576 | Farnesoid x receptor in human metabolism and disease: the interplay between gene polymorphisms, clinical phenotypes and disease susceptibility. |
| Q34482950 | Function annotation of hepatic retinoid x receptor α based on genome-wide DNA binding and transcriptome profiling |
| Q33574661 | Gene regulation of CYP4F11 in human keratinocyte HaCaT cells |
| Q35044846 | Genetic background of cholesterol gallstone disease |
| Q35448570 | Genetics of familial intrahepatic cholestasis syndromes |
| Q34189248 | Genome-wide interrogation of hepatic FXR reveals an asymmetric IR-1 motif and synergy with LRH-1. |
| Q40954998 | Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. |
| Q39906689 | Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy |
| Q90296417 | Hepatic Autophagy Deficiency Compromises Farnesoid X Receptor Functionality and Causes Cholestatic Injury |
| Q38300264 | Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. |
| Q40547550 | Identification of DRIP205 as a coactivator for the Farnesoid X receptor. |
| Q46201476 | Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors |
| Q24540997 | Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol |
| Q44259003 | Identification of gene-selective modulators of the bile acid receptor FXR. |
| Q44897916 | Identification of intermediates in the bile acid synthetic pathway as ligands for the farnesoid X receptor |
| Q54473491 | Inhibition of Leydig tumor growth by farnesoid X receptor activation: the in vitro and in vivo basis for a novel therapeutic strategy. |
| Q24548189 | LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes |
| Q44734860 | Ligand-binding domain of farnesoid X receptor (FXR) had the highest sensitivity and activity among FXR variants in a fluorescence-based assay |
| Q28580149 | Lipopolysaccharide represses cholesterol 7-alpha hydroxylase and induces binding activity to the bile acid response element II |
| Q37120614 | Lithocholic acid decreases expression of UGT2B7 in Caco-2 cells: a potential role for a negative farnesoid X receptor response element |
| Q39901207 | Low retinol levels differentially modulate bile salt-induced expression of human and mouse hepatic bile salt transporters |
| Q24655100 | Molecular mechanisms involved in farnesol-induced apoptosis |
| Q40694910 | Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation |
| Q38289421 | Nuclear bile acid signaling through the farnesoid X receptor |
| Q34666809 | Nuclear receptor regulation of hepatic function |
| Q36786270 | Nuclear receptors as drug targets in cholestatic liver diseases |
| Q37230857 | Nuclear receptors as therapeutic targets in cholestatic liver diseases. |
| Q35184131 | Nuclear receptors in cholesterol catabolism: molecular biology of the enterohepatic circulation of bile salts and its role in cholesterol homeostasis |
| Q37222442 | OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids |
| Q36216779 | Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway |
| Q34311566 | Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism. |
| Q24623871 | Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR |
| Q34303001 | Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease |
| Q28198291 | Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta |
| Q37076509 | Regulation of human class I alcohol dehydrogenases by bile acids |
| Q40768989 | Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor |
| Q38301174 | Regulation of the sodium/sulfate co-transporter by farnesoid X receptor alpha |
| Q44273183 | Repression of farnesoid X receptor during the acute phase response |
| Q33786733 | Role of FXR and FTF in bile acid-mediated suppression of cholesterol 7alpha-hydroxylase transcription |
| Q28086898 | Role of farnesoid X receptor and bile acids in alcoholic liver disease |
| Q35080494 | Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells |
| Q38794081 | Serum bile acids in term and preterm neonates: A case-control study determining reference values and the influence of early-onset sepsis |
| Q24644790 | Structure of the heterodimeric ecdysone receptor DNA-binding complex |
| Q27689325 | Structure of the retinoid X receptor α-liver X receptor β (RXRα-LXRβ) heterodimer on DNA |
| Q40634177 | Structure-activity relationship of bile acids and bile acid analogs in regard to FXR activation |
| Q34025914 | Study of FoxA pioneer factor at silent genes reveals Rfx-repressed enhancer at Cdx2 and a potential indicator of esophageal adenocarcinoma development |
| Q28114885 | Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor |
| Q38357712 | Synergism between nuclear receptors bound to specific hormone response elements of the hepatic control region-1 and the proximal apolipoprotein C-II promoter mediate apolipoprotein C-II gene regulation by bile acids and retinoids |
| Q92816765 | The Biosynthesis, Signaling, and Neurological Functions of Bile Acids |
| Q28199120 | The Human Apolipoprotein AV Gene Is Regulated by Peroxisome Proliferator-activated Receptor-α and Contains a Novel Farnesoid X-activated Receptor Response Element |
| Q40555056 | The farnesoid X receptor induces very low density lipoprotein receptor gene expression |
| Q45006336 | The farnesoid X receptor negatively regulates osteoclastogenesis in bone remodeling and pathological bone loss |
| Q37184702 | The farnesoid X receptor regulates transcription of 3beta-hydroxysteroid dehydrogenase type 2 in human adrenal cells |
| Q34343494 | The farnesoid X receptor: a novel drug target? |
| Q38603051 | The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways |
| Q38943288 | The nuclear bile acid receptor FXR controls the liver derived tumor suppressor histidine-rich glycoprotein |
| Q28280371 | The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes |
| Q33944953 | The orphan nuclear receptor LRH-1 potentiates the sterol-mediated induction of the human CETP gene by liver X receptor |
| Q38149738 | The orphan nuclear receptors at their 25-year reunion |
| Q38643266 | The pharmacological management of NAFLD in children and adolescents |
| Q34740387 | The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions |
| Q37300843 | The role of FXR in disorders of bile acid homeostasis |
| Q39943758 | Transactivation of the hepatitis B virus core promoter by the nuclear receptor FXRalpha |
| Q28236615 | Transcription of the vascular endothelial growth factor gene in macrophages is regulated by liver X receptors |
| Q36316454 | Transcriptional Regulation of Cytosolic Sulfotransferase 1C2 by Intermediates of the Cholesterol Biosynthetic Pathway in Primary Cultured Rat Hepatocytes |
| Q34089245 | Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): roles of heaptocyte nuclear factor 4alpha in mediating bile acid repression |
| Q39642788 | Upregulation of scavenger receptor class B type I expression by activation of FXR in hepatocyte |
| Q44356501 | Use of dominant negative nuclear receptors to study xenobiotic-inducible gene expression in primary cultured hepatocytes |
| Q38323349 | VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium |
| Q36931713 | Xenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspective |